gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 26, 2012 15:37:32 GMT -5
Celsion Corp. (CLSN), which trades in a 52-week range of $1.63/share (52-week low) and $4.37/share (52-week high), has a market cap of $122.27 million. CLSN currently has $24.59 million in total cash on its books (it should be noted that the company currently has -$24.10 million in operating cash flow, and -$15.38 million in free cash flow) and actually has $135,550 in total debt. That equates to a debt to total cash ratio of 0.5%, which in my opinion, is a positive catalyst moving forward. Recently trading at a 82.1% premium to its 200-day moving average, CLSN has been making some nice progress with regard to its clinical trials of Thermodox, which is the company's drug designed to battle Hepatitis C.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 30, 2012 9:36:44 GMT -5
Advaxis, Inc., ADXS, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy. These data were reported on Thursday, July 26, 2012 at the Immunotherapy Subcommittee Workshop of the Gynecologic Oncology Group (GOG) meeting in Boston. The GOG is conducting a Phase 2 study of ADXS-HPV in a similar patient population in the US.
The objectives of this Phase 2 trial include an assessment of the safety and efficacy of ADXS-HPV (1x109 cfu) with and without cisplatin (40 mg/m2, weekly x5). The primary endpoint of this study is survival.
As of July 12, 2012, survival at 6, 9, and 12 months is 64%, 46%, and 29%, respectively. This compares to survival of 65%, 40%, and 31% that was reported at the 2012 ASCO Annual Meeting in June. National Comprehensive Network Guidelines cite historical 12 month survival data of 0-22% with single agent therapy in this patient population.
Objective tumor responses and stable disease continue to be observed in the India trial. As of July 12, 2012, 63 patients had survived at least 3 months and had at least one follow up CAT scan to determine tumor response. Tumor responses included:
5 complete responses (CR -0.18%, news): 3 in the ADXS alone group; 2 in the ADXS+ cisplatin group. 6 partial responses (PR): 3 in the ADXS alone group; 3 in the ADXS+ cisplatin group. I do not undeerstand this stock at all any one have any ideas?
|
|
safeharbor37
Well-Known Member
Joined: Dec 20, 2010 23:18:19 GMT -5
Posts: 1,290
|
Post by safeharbor37 on Aug 9, 2012 16:03:00 GMT -5
MotleyFool has pointed out ALU and HILL amongst those "penny stocks" due for a turnaround. They do look interesting.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Aug 10, 2012 8:41:02 GMT -5
I do like hill think i will get a few. alu not so much i have been torched by lucent a few times
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Aug 20, 2012 13:01:30 GMT -5
BRCD:Brocade Communications Systems, Inc. (Brocade) is a supplier of networking equipment, including end-to-end Internet Protocol-based Ethernet networking solutions and storage area networking solutions for businesses and organizations of all types and sizes, including global enterprises, and service providers, such as telecommunication firms, cable operators and mobile carriers. Brocade offers a range of networking hardware and software products and services. Brocade products and services are marketed, sold and supported globally to end-user customers through distribution partners, including original equipment manufacturers, distributors, value-added resellers (VARs) and directly to end-users by the Brocade direct sales force. It operates in four segments: Data Storage, Global Services, IP Layer 2-3 and IP Layer 4-7/ Application Delivery Products. In February 2012, it expanded investment in the Asia Pacific region with the opening of a regional briefing center (RB) located in Singapore. currently at 5.63 but I will get in at 5,if it get there
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Aug 28, 2012 9:23:23 GMT -5
XOMA: combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. The company recently received Orphan Drug Designation by the U.S. Food & Drug Administration for Gevokizumab.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Sept 6, 2012 15:50:59 GMT -5
(ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase III clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase II clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain, and AcelRx plans to initiate a Phase II study funded by a grant from USAMRMC, contingent on approval of the proposed clinical protocol for the study by USAMRMC.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Sept 24, 2012 10:14:03 GMT -5
Rambus Inc. (Rambus)RMBS: is an intellectual property and technology licensing company. It is engaged in the design, development and licensing of memory and logic interfaces, lighting and optoelectronics, and other technologies. The Company’s primary focus is the creation, design, development and licensing of patented innovations, technologies and architectures that are foundational to all digital electronics products and systems. Its patented innovations and technologies are provided to customers’ products, components and systems offered and used in semiconductors, computers, mobile applications, gaming and graphics, consumer electronics, lighting displays and general lighting. Rambus operates in two segments: Semiconductor Business Group (SBG) and New Business Group (NBG). In June 2011, the Company acquired Cryptography Research, Inc. In February 2012, the Company acquired Unity Semiconductor, a memory technology company.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Sept 25, 2012 10:33:17 GMT -5
I know i mentioned this one before but it might be worth another look. Antares Pharma, Inc. ATRS today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX +1.85%, news). The clinical trial was conducted as a multi-center, open-label, single-arm, in-clinic study to evaluate the actual human use of methotrexate administered via the VIBEX Medi-Jet in adult patients with rheumatoid arthritis (RA +0.04%, news).
The study assessed the safe usability of VIBEX MTX for self-administration of parenteral MTX in adult RA patients after standardized training by site personnel and review of written instructions. Secondary objectives included evaluation of the reliability, ease of use and robustness of the VIBEX Medi-Jet; assess the safety and local tolerance of Medi-Jet administered MTX and to evaluate the effectiveness of the patient education tools including written instructions for use.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Oct 9, 2012 12:18:43 GMT -5
PSTI: Pluristem is a developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases.
The company's main technology, The PluriX Bioreactor System is designed to be a system of stromal cell cultures and substrates that create an artificial physiological environment where adherent stromal cells (ASCs) can grow and reproduce outside of the human body. Unlike conventional two-dimensional (2D) culturing methods, the company's PluriX Bioreactor creates a three-dimensional (3D) microenvironment that closely resembles the structure and function of the body's bone marrow environment. By mimicking the natural environment that exists within human bones, the system tricks stem cells into growing and reproducing in the same way they would in living organs. Because the size and scale of the PluriX Bioreactor is larger than that of human bone marrow, stem cell growth can be greatly expanded.
On August 6th, the company announced that the life of a patient suffering from bone marrow failure in which there was a dangerous reduction in the number of red blood cells, white blood cells, and platelets (pancytopenia) has been saved using Placental eXpanded cells. This is the second time in the past three months that a patient suffering from bone marrow failure was successfully treated in a compassionate use treatment with PLX cells with a return of bone marrow function.
An announcement from Pluristem on Aug. 13, 2012 indicated that those afflicted with peripheral arterial disease, or PAD, may soon have an alternative to Bristol-Myer Squibb's (BMY) troubled anti-clotting drug Plavix, whose drawbacks prompted the FDA to assign a black box label two years ago. People who have reduced functioning of their CYP2C19 liver enzyme cannot effectively convert Plavix to its active form. As a result, Plavix may be less effective in altering platelet activity in those people. These "poor metabolizers" may not receive the full benefit of Plavix treatment and may remain at risk for heart attack, stroke, and cardiovascular death.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Oct 23, 2012 14:12:08 GMT -5
Dynavax (DVAX)
Dynavax Technologies has a number of promising drugs, with HEPLISAVTM being their prize, as it treats Hepatitis B, which afflicts 350 million people worldwide. An FDA decision on their phase 3 testing is looming in February, but as with any promising phase 3 decision, the run-up begins well before then.
I also like that DVAX has about $160 million cash on hand, and if they continue spending $5 million a month, they have plenty of breathing room, assuming they aren't bought out. Even if their drug is rejected, the cash on hand allows them to continue development.
Additionally, according to Dynavax's website:
The U.S. Food and Drug Administration [FDA] has informed the Company that its Vaccines and Related Biological Products Advisory Committee [VRBPAC] is scheduled to discuss HEPLISAV at its meeting on November 14-15, 2012
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Oct 26, 2012 7:05:16 GMT -5
a little additional suport for my recommendation of dvax:Technologies (DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
In order to reveal the opportunity and the potential behind Dynavax, I held an exclusive interview this week with Dr. Philip Nadeau, a Managing Director and Senior Research Analyst on the biotechnology team at Cowen and Company. Dr. Nadeau has been at Cowen for twelve years and has been recognized in the Wall Street Journal's "Best on the Street" rankings. He has a Ph.D. in neurobiology from Harvard University and an S.B./M.Eng in electrical engineering and computer science from MIT. We have focused mostly on the company's lead product candidate, Heplisav, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines. Heplisav combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.
The U.S. Food and Drug Administration (FDA) has set November 14-15, 2012, to discuss Heplisav's approvability at the Vaccines and Related Biological Products Advisory Committee panel. The FDA has also established February 24, 2013, as the PDUFA date for Heplisav
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Nov 8, 2012 14:47:17 GMT -5
while I am not into energy stocks at this time with Obama back in office it might be time to look at some solar stocks, one i am currently investigating is SPWR: SunPower Corp. is a vertically integrated solar products and services company that designs manufactures and delivers high-performance solar electric systems worldwide for residential commercial and utility-scale power plant customers.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Nov 13, 2012 16:41:19 GMT -5
DVAX: Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said. The company’s shares jumped the most in about 14 months on the report.
Heplisav worked as well after two doses as three doses of GlaxoSmithKline Plc (GSK)’s Engerix-B vaccine to protect patients against the virus, FDA staff said today in a report released ahead of an advisory panel meeting scheduled Nov. 15 on Dynavax’s vaccine. Heplisav also had a similar safety profile to Engerix-B, agency staff said.
Heplisav would be Berkeley, California-based Dynavax’s first product if the vaccine is cleared by Feb. 24 when the FDA is scheduled to decide on approval. The vaccine may generate an estimated $775 million in peak worldwide sales in 2020, Katherine Xu, an analyst with William Blair & Co. in New York, said in an e-mail.
still under 5 but only by a little
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Nov 21, 2012 15:00:42 GMT -5
still hanging around just wanted to say to all have a happy, safe thanksgiving
|
|
ModE98
Administrator
Start Investing admin
Joined: Dec 20, 2010 16:11:39 GMT -5
Posts: 4,441
|
Post by ModE98 on Nov 21, 2012 16:21:05 GMT -5
Yes, Happy Thanksgiving, everyone.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Nov 28, 2012 16:36:39 GMT -5
CEL-SCI Corporation (nyse mkt:CVM) today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection)*. The patent, Japanese patent number 5,122,279, is titled, "A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation and/or Chemotherapy and a Novel Cytokine Mixture". Key patents on Multikine have now been issued in the largest pharmaceutical markets in the world: the United States, European Union, China and Japan.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Dec 6, 2012 14:23:23 GMT -5
BG Medicine (BGMD), a firm that engages in the discovery, development, and commercialization of novel cardiovascular diagnostics to address unmet medical needs. This company has just changed its business model and could be headed higher as a result.
In an earning release last week, BG Medicine, Inc. announced a new commercial strategy to speed the adoption of its cardiovascular diagnostic tests - the BGM Galectin-3 test and the CardioSCORE test. The firm's management team has taken steps to realign BG Medicine as a commercially-focused company, capable of playing a larger role in facilitating the market adoption their innovative cardiovascular diagnostic tests. Together, these actions appear to place BGMD in a much stronger position to control our own destiny anddrive our own commercial success.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Dec 12, 2012 14:32:56 GMT -5
DRTX: On December 11th it was announced that the company's Phase III study of dalbavancin, which is under investigation for the treatment of acute bacterial skin infections, achieved its primary endpoint within 48-72 hours after initiation of therapy. According to the company's most recent press release regarding the study, "In the clinical trial, the treatment-related adverse event rate for dalbavancin was 12.3% and for vancomycin/linezolid was 18.3%. Adverse events reported in the 3% of patients receiving dalbavancin in this trial were nausea, diarrhea, headache, and pruritus. Discontinuations due to treatment emergent adverse events were 1.8% and 2.1% for dalbavancin and vancomycin/linezolid, respectively. This adverse event profile is consistent with results from prior Phase 3 studies of dalbavancin".
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Dec 21, 2012 14:56:17 GMT -5
merry christmas to all, and to all a good night, i am done for the year, thanks to all for a profitable one
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jan 4, 2013 16:27:13 GMT -5
ArQule (NASDAQ: ARQL) engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase 3 clinical trial for the treatment of liver cancer and colorectal cancer (CRC). The company also develops ARQ 621, an inhibitor of the Eg5 kinesin motor protein that has completed Phase I trial; ARQ 736, an inhibitor of the RAF kinases, which is in Phase I clinical trial; ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway; and ARQ 087, an inhibitor of fibroblast growth factor receptor that is in pre-clinical stage. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jan 22, 2013 14:41:09 GMT -5
Frontier Communications Corporation (Frontier),FTR: is a communications company providing services primarily to rural areas and small and medium-sized towns and cities in the United States. The Company offers a range of voice, data, Internet, and television services and products, some that are available a la carte, and others that are available as bundled or packaged solutions. It operated in 27 states, and was the Incumbent Local Exchange Carrier (ILEC), with approximately 5.3 million access lines and 1.8 million broadband connections as of December 31, 2011. During the year ended December 31, 2011, the Company added approximately 45,200 new High-Speed Internet (HSI) subscribers, net. At December 31, 2011, it had approximately 1,764,200 HSI customers. Throughout its properties, Frontier offers a video product through DISH Network (DISH) and, in addition, it offers fiber optic video services in three states. It added approximately 26,100 video subscribers, net during 2011.
|
|
The Virginian
Senior Member
"Formal education makes you a living, self education makes you a fortune."
Joined: Dec 20, 2010 18:05:58 GMT -5
Posts: 3,629
Today's Mood: Cautiously Optimistic
Location: Somewhere between Virginia & Florida !
Favorite Drink: Something Wet & Cold
|
Post by The Virginian on Jan 22, 2013 15:13:36 GMT -5
Are you recommending this one Gambler ?? Pays 8.93% Dividend The P/E ratio is out of wack - Above 30% but I'm almost tempted to buy a few shares. Maybe they will be a good buyout target if nothing else. FINANCIAL HIGHLIGHTS Symbol | Value ($) |
---|
Sales* | 5.06 Bil | Income* | 150.91 Mil | Sales Growth* | +38.10% | Income Growth* | -2.50% | Net Profit Margin | 3.35% | Debt/Equity Ratio | 2.06 | Beta | 0.75 | EPS | 0.15 | Forward P/E | 17.42 | P/E | 30.20 | Market Cap | 4.52 Bil | Shares Outstanding | 998.45 Mil |
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jan 22, 2013 16:36:28 GMT -5
yes i am recommending FTR for under 5 it is a steal, for the big $ guys look at CTL, i am into both and have not been disappointed with either.
|
|
The Virginian
Senior Member
"Formal education makes you a living, self education makes you a fortune."
Joined: Dec 20, 2010 18:05:58 GMT -5
Posts: 3,629
Today's Mood: Cautiously Optimistic
Location: Somewhere between Virginia & Florida !
Favorite Drink: Something Wet & Cold
|
Post by The Virginian on Jan 25, 2013 14:05:39 GMT -5
Gambler - Do you or anyone else know anything about FNMA (Fannie Mae) -- It's trading over the counter for .28 per share ! Is it worth the gamble ?
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jan 26, 2013 12:51:52 GMT -5
I personnaly think that fannie and freddie are going to recover as the housing industry get better. that being said i also think it will be a very, very long time and therefore not worth tying up any great amount offunds that could be used with better results elswere, as for an investment at .28 i think it is totaly safe and might be some thing for you to get for your grandkids or great grand kids
|
|
The Virginian
Senior Member
"Formal education makes you a living, self education makes you a fortune."
Joined: Dec 20, 2010 18:05:58 GMT -5
Posts: 3,629
Today's Mood: Cautiously Optimistic
Location: Somewhere between Virginia & Florida !
Favorite Drink: Something Wet & Cold
|
Post by The Virginian on Jan 26, 2013 13:01:08 GMT -5
Yes Fannie Mae is .28 per share and Freddie Mac is .29 per share . for a couple hundred dollars you can pick up about 350 shares of each. If they are not going bankrupt ( I couldn't find anything that said that) they might be very good Long Term plays. At any case I just might gamble a couple hundred dollars on them.
|
|
The Virginian
Senior Member
"Formal education makes you a living, self education makes you a fortune."
Joined: Dec 20, 2010 18:05:58 GMT -5
Posts: 3,629
Today's Mood: Cautiously Optimistic
Location: Somewhere between Virginia & Florida !
Favorite Drink: Something Wet & Cold
|
Post by The Virginian on Jan 29, 2013 8:39:45 GMT -5
Gambler - You mentioned that you day trade - are you buying penny stocks as short term plays or are they long term investments?
If Long term what are you looking for? Perhaps acquisition by larger companies , etc. ?
If short term what is it that you look for ?
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Feb 2, 2013 14:47:57 GMT -5
most of the pennies I buy are long term, I tend to go with biotechs becuse of the greater rewards a few such as aria,dndn and depo and dvax i flipped quickly, I tend to look for the potential of the drug for approval by the fda. if the drug makes it acquisitions tend to happen. short term I check the fda schedule any company the as a sligthly viable drug will make a run up to the avisator board, dvax was a good example it made a good run up to the board(i sold), drop after( I bought again) and is climing to it's approval/ disapproval date the day before I wil sell 1/2 of my holdings becue i think this drug will get aproved if not this time around than next. If i feel the drug will fail(ctic comes to mind) i sell all. my time frame for any of these is 3months to several years (cvm and ovit are examples of my long, long holds). My day trade are mostly off the day traders thread as biotechs do not have the volume.
Pluristem Therapeutics Inc. PSTI:Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company's PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.
|
|
burger
Junior Member
Joined: Feb 12, 2011 20:34:09 GMT -5
Posts: 143
|
Post by burger on Feb 7, 2013 19:52:53 GMT -5
Gambler, I hope you are still holding ADXS. It has been a nice 2 weeks or so and hopefully more to come!
|
|